**Philippines**

**Tuberculosis profile**

**Population 2018**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>591 (332–924) 554 (311–866)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>10 (4.1–19) 9.4 (3.8–17)</td>
</tr>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>18 (7.7–32) 17 (7.3–30)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>2.6 (22–30) 24 (20–28)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>0.6 (0–4.2) 0.57 (0–4)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- % tested with rapid diagnostics at time of diagnosis: 36%
- % with known HIV status: 27%
- % pulmonary: 98%
- % bacteriologically confirmed: 36%
- % children aged 0-14 years: 12%
- % men: 58%

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2018**: 63% (40–110)
- **TB patients facing catastrophic total costs, 2017**: 35% (33–37)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 5% (3–7)

**TB/HIV care in new and relapse TB patients, 2018**

- % patients with known HIV status who are HIV-positive on antiretroviral therapy: 1,477 1%

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: <1%
- % of previously treated cases tested for rifampicin resistance: 24%

**Patients started on treatment with resistance to second-line drugs**

- MDR/RR-TB: 7,276, XDR-TB: 52
- MDR/RR-TB: 6,125, XDR-TB: 52

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017: 91% 315,923
- Previously treated cases, excluding relapse, registered in 2017: 82% 9,486
- HIV-positive TB cases registered in 2017: 82% 1,268
- MDR/RR-TB cases started on second-line treatment in 2016: 58% 5,071
- XDR-TB: 20% 10

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.7–10)

**TB financing, 2019**

- National TB budget (US$ millions): 205
- Funding source: 12% domestic, 25% international, 63% unfunded

---

* Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* Calculated for pulmonary cases only
* MDR-TB cases are those resistant to rifampicin
* Includes cases with unknown previous TB treatment history
* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed